ABCB1 Polymorphism Is Associated with Higher Carbamazepine Clearance in Children

Area of Science:

• Pharmacogenomics
• Clinical Pharmacology
• Pediatric Epilepsy

Background:

• Carbamazepine (CBZ) is a widely used antiepileptic drug.
• Individual variability in CBZ pharmacokinetics necessitates personalized dosing strategies.
• The ABCB1 gene, encoding P-glycoprotein, plays a role in drug transport and metabolism.

Purpose of the Study:

• To investigate the association between ABCB1 gene polymorphisms and carbamazepine (CBZ) pharmacokinetics in Serbian pediatric epileptic patients.
• To determine the influence of specific ABCB1 genotypes and haplotypes on CBZ serum concentrations and clearance.
• To develop a population pharmacokinetic model incorporating ABCB1 variations for improved CBZ dosing in children.

Main Methods:

• Study included 47 pediatric epileptic patients on CBZ treatment.
• Genotyping for ABCB1 polymorphisms (1236C>T, 2677G>A/T, 3435C>T) using the TaqMan method.
• Pharmacokinetic analysis using NONMEM software and a one-compartment model, utilizing previously determined CBZ serum concentrations.

Main Results:

• Allele frequencies for ABCB1 1236C>T, 2677G>A/T, and 3435C>T were 47.9%, 48.9%, and 52.1%, respectively.
• A population pharmacokinetic model was established, incorporating sex, ABCB1 diplotype, CYP1A2 genotype, and daily CBZ dose.
• The ABCB1 1236T-2677T-3435T haplotype was significantly associated with increased CBZ clearance in pediatric patients.

Conclusions:

• ABCB1 gene polymorphism is a significant factor affecting carbamazepine pharmacokinetics in children with epilepsy.
• The identified 1236T-2677T-3435T haplotype may lead to faster CBZ metabolism, potentially requiring dose adjustments.
• These findings support the use of pharmacogenetic testing to optimize CBZ therapy in pediatric populations.